Impact  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
community  ||| S:10 E:20 ||| NN
management  ||| S:20 E:31 ||| NN
of  ||| S:31 E:34 ||| IN
fever  ||| S:34 E:40 ||| NN
( ||| S:40 E:41 ||| -LRB-
using  ||| S:41 E:47 ||| VBG
antimalarials  ||| S:47 E:61 ||| NN
with  ||| S:61 E:66 ||| IN
or  ||| S:66 E:69 ||| CC
without  ||| S:69 E:77 ||| IN
antibiotics ||| S:77 E:88 ||| CD
)  ||| S:88 E:90 ||| -RRB-
on  ||| S:90 E:93 ||| IN
childhood  ||| S:93 E:103 ||| NN
mortality ||| S:103 E:112 ||| NN
:  ||| S:112 E:114 ||| :
a  ||| S:114 E:116 ||| DT
cluster-randomized  ||| S:116 E:135 ||| JJ
controlled  ||| S:135 E:146 ||| JJ
trial  ||| S:146 E:152 ||| NN
in  ||| S:152 E:155 ||| IN
Ghana  ||| S:155 E:161 ||| NNP
Malaria  ||| S:161 E:169 ||| NNP
and  ||| S:169 E:173 ||| CC
pneumonia  ||| S:173 E:183 ||| NNS
are  ||| S:183 E:187 ||| VBP
leading  ||| S:187 E:195 ||| VBG
causes  ||| S:195 E:202 ||| NNS
of  ||| S:202 E:205 ||| IN
childhood  ||| S:205 E:215 ||| NN
mortality ||| S:215 E:224 ||| NN
.  ||| S:224 E:226 ||| .
Home  ||| S:226 E:231 ||| NNP
Management  ||| S:231 E:242 ||| NNP
of  ||| S:242 E:245 ||| IN
fever  ||| S:245 E:251 ||| NN
as  ||| S:251 E:254 ||| IN
Malaria  ||| S:254 E:262 ||| NNP
( ||| S:262 E:263 ||| -LRB-
HMM ||| S:263 E:266 ||| NNP
)  ||| S:266 E:268 ||| -RRB-
enables  ||| S:268 E:276 ||| VBZ
presumptive  ||| S:276 E:288 ||| JJ
treatment  ||| S:288 E:298 ||| NN
with  ||| S:298 E:303 ||| IN
antimalarial  ||| S:303 E:316 ||| JJ
drugs  ||| S:316 E:322 ||| NNS
but  ||| S:322 E:326 ||| CC
excludes  ||| S:326 E:335 ||| JJ
pneumonia ||| S:335 E:344 ||| NN
.  ||| S:344 E:346 ||| .
We  ||| S:346 E:349 ||| PRP
aimed  ||| S:349 E:355 ||| VBD
to  ||| S:355 E:358 ||| TO
evaluate  ||| S:358 E:367 ||| VB
the  ||| S:367 E:371 ||| DT
impact  ||| S:371 E:378 ||| NN
of  ||| S:378 E:381 ||| IN
adding  ||| S:381 E:388 ||| VBG
an  ||| S:388 E:391 ||| DT
antibiotic ||| S:391 E:401 ||| NN
,  ||| S:401 E:403 ||| ,
amoxicillin  ||| S:403 E:415 ||| NNS
( ||| S:415 E:416 ||| -LRB-
AMX ||| S:416 E:419 ||| NNP
)  ||| S:419 E:421 ||| -RRB-
to  ||| S:421 E:424 ||| TO
an  ||| S:424 E:427 ||| DT
antimalarial ||| S:427 E:439 ||| NN
,  ||| S:439 E:441 ||| ,
artesunate  ||| S:441 E:452 ||| FW
amodiaquine  ||| S:452 E:464 ||| FW
( ||| S:464 E:465 ||| -LRB-
AAQ  ||| S:465 E:469 ||| NNP
+  ||| S:469 E:471 ||| NNP
AMX ||| S:471 E:474 ||| NNP
)  ||| S:474 E:476 ||| -RRB-
for  ||| S:476 E:480 ||| IN
treating  ||| S:480 E:489 ||| VBG
fever  ||| S:489 E:495 ||| NN
among  ||| S:495 E:501 ||| IN
children  ||| S:501 E:510 ||| NNS
2-59  ||| S:510 E:515 ||| CD
months  ||| S:515 E:522 ||| NNS
of  ||| S:522 E:525 ||| IN
age  ||| S:525 E:529 ||| NN
within  ||| S:529 E:536 ||| IN
the  ||| S:536 E:540 ||| DT
HMM  ||| S:540 E:544 ||| NNP
strategy  ||| S:544 E:553 ||| NN
on  ||| S:553 E:556 ||| IN
all-cause  ||| S:556 E:566 ||| JJ
mortality ||| S:566 E:575 ||| NN
.  ||| S:575 E:577 ||| .
In  ||| S:577 E:580 ||| IN
a  ||| S:580 E:582 ||| DT
stepped-wedge  ||| S:582 E:596 ||| JJ
cluster-randomized ||| S:596 E:614 ||| NN
,  ||| S:614 E:616 ||| ,
open  ||| S:616 E:621 ||| JJ
trial ||| S:621 E:626 ||| NN
,  ||| S:626 E:628 ||| ,
children  ||| S:628 E:637 ||| NNS
2-59  ||| S:637 E:642 ||| CD
months  ||| S:642 E:649 ||| NNS
of  ||| S:649 E:652 ||| IN
age  ||| S:652 E:656 ||| NN
with  ||| S:656 E:661 ||| IN
fever  ||| S:661 E:667 ||| NN
treated  ||| S:667 E:675 ||| VBN
with  ||| S:675 E:680 ||| IN
AAQ  ||| S:680 E:684 ||| NNP
or  ||| S:684 E:687 ||| CC
AAQ  ||| S:687 E:691 ||| NNP
+  ||| S:691 E:693 ||| NNP
AMX  ||| S:693 E:697 ||| NNP
within  ||| S:697 E:704 ||| IN
HMM  ||| S:704 E:708 ||| NNP
were  ||| S:708 E:713 ||| VBD
compared  ||| S:713 E:722 ||| VBN
with  ||| S:722 E:727 ||| IN
standard  ||| S:727 E:736 ||| JJ
care ||| S:736 E:740 ||| NN
.  ||| S:740 E:742 ||| .
Mortality  ||| S:742 E:752 ||| NN
reduced  ||| S:752 E:760 ||| VBD
significantly  ||| S:760 E:774 ||| RB
by  ||| S:774 E:777 ||| IN
30 ||| S:777 E:779 ||| CD
%  ||| S:779 E:781 ||| NN
( ||| S:781 E:782 ||| -LRB-
rate  ||| S:782 E:787 ||| NN
ratio  ||| S:787 E:793 ||| NN
[ ||| S:793 E:794 ||| -LRB-
RR ||| S:794 E:796 ||| NNP
]  ||| S:796 E:798 ||| -RRB-
=  ||| S:798 E:800 ||| SYM
0.70 ||| S:800 E:804 ||| CD
,  ||| S:804 E:806 ||| ,
95 ||| S:806 E:808 ||| CD
%  ||| S:808 E:810 ||| NN
confidence  ||| S:810 E:821 ||| NN
interval  ||| S:821 E:830 ||| NNS
[ ||| S:830 E:831 ||| -LRB-
CI ||| S:831 E:833 ||| NNP
]  ||| S:833 E:835 ||| -RRB-
=  ||| S:835 E:837 ||| SYM
0.53-0.92 ||| S:837 E:846 ||| CD
,  ||| S:846 E:848 ||| ,
P  ||| S:848 E:850 ||| NN
=  ||| S:850 E:852 ||| SYM
0.011 ||| S:852 E:857 ||| CD
)  ||| S:857 E:859 ||| -RRB-
in  ||| S:859 E:862 ||| IN
AAQ  ||| S:862 E:866 ||| NNP
clusters  ||| S:866 E:875 ||| NNS
and  ||| S:875 E:879 ||| CC
by  ||| S:879 E:882 ||| IN
44 ||| S:882 E:884 ||| CD
%  ||| S:884 E:886 ||| NN
( ||| S:886 E:887 ||| -LRB-
RR  ||| S:887 E:890 ||| NNP
=  ||| S:890 E:892 ||| SYM
0.56 ||| S:892 E:896 ||| CD
,  ||| S:896 E:898 ||| ,
95 ||| S:898 E:900 ||| CD
%  ||| S:900 E:902 ||| NN
CI  ||| S:902 E:905 ||| NNP
=  ||| S:905 E:907 ||| SYM
0.41-0.76 ||| S:907 E:916 ||| CD
,  ||| S:916 E:918 ||| ,
P  ||| S:918 E:920 ||| NN
=  ||| S:920 E:922 ||| SYM
0.011 ||| S:922 E:927 ||| CD
)  ||| S:927 E:929 ||| -RRB-
in  ||| S:929 E:932 ||| IN
AAQ  ||| S:932 E:936 ||| NNP
+  ||| S:936 E:938 ||| NNP
AMX  ||| S:938 E:942 ||| NNP
clusters  ||| S:942 E:951 ||| VBD
compared  ||| S:951 E:960 ||| VBN
with  ||| S:960 E:965 ||| IN
control  ||| S:965 E:973 ||| NN
clusters ||| S:973 E:981 ||| NNS
.  ||| S:981 E:983 ||| .
The  ||| S:983 E:987 ||| DT
21 ||| S:987 E:989 ||| CD
%  ||| S:989 E:991 ||| NN
mortality  ||| S:991 E:1001 ||| NN
reduction  ||| S:1001 E:1011 ||| NN
between  ||| S:1011 E:1019 ||| IN
AAQ  ||| S:1019 E:1023 ||| NNP
and  ||| S:1023 E:1027 ||| CC
AAQ  ||| S:1027 E:1031 ||| NNP
+  ||| S:1031 E:1033 ||| NNP
AMX  ||| S:1033 E:1037 ||| NNP
( ||| S:1037 E:1038 ||| -LRB-
RR  ||| S:1038 E:1041 ||| NNP
=  ||| S:1041 E:1043 ||| SYM
0.79 ||| S:1043 E:1047 ||| CD
,  ||| S:1047 E:1049 ||| ,
95 ||| S:1049 E:1051 ||| CD
%  ||| S:1051 E:1053 ||| NN
CI  ||| S:1053 E:1056 ||| NNP
=  ||| S:1056 E:1058 ||| SYM
0.56-1.12 ||| S:1058 E:1067 ||| CD
,  ||| S:1067 E:1069 ||| ,
P  ||| S:1069 E:1071 ||| NN
=  ||| S:1071 E:1073 ||| SYM
0.195 ||| S:1073 E:1078 ||| CD
)  ||| S:1078 E:1080 ||| -RRB-
was  ||| S:1080 E:1084 ||| VBD
however  ||| S:1084 E:1092 ||| RB
not  ||| S:1092 E:1096 ||| RB
statistically  ||| S:1096 E:1110 ||| RB
significant ||| S:1110 E:1121 ||| JJ
.  ||| S:1121 E:1123 ||| .
Community  ||| S:1123 E:1133 ||| NNP
fever  ||| S:1133 E:1139 ||| NN
management  ||| S:1139 E:1150 ||| NN
with  ||| S:1150 E:1155 ||| IN
antimalarials  ||| S:1155 E:1169 ||| VBG
significantly  ||| S:1169 E:1183 ||| RB
reduces  ||| S:1183 E:1191 ||| VBZ
under-five  ||| S:1191 E:1202 ||| JJ
mortality ||| S:1202 E:1211 ||| NN
.  ||| S:1211 E:1213 ||| .
Given  ||| S:1213 E:1219 ||| VBN
the  ||| S:1219 E:1223 ||| DT
lower  ||| S:1223 E:1229 ||| JJR
mortality  ||| S:1229 E:1239 ||| NN
trend ||| S:1239 E:1244 ||| NN
,  ||| S:1244 E:1246 ||| ,
adding  ||| S:1246 E:1253 ||| VBG
an  ||| S:1253 E:1256 ||| DT
antibiotic  ||| S:1256 E:1267 ||| NN
is  ||| S:1267 E:1270 ||| VBZ
more  ||| S:1270 E:1275 ||| RBR
beneficial ||| S:1275 E:1285 ||| JJ
.  ||| S:1285 E:1287 ||| .
